An IQ consortium analysis of starting dose selection for oncology small molecule first-in-patient trials suggests an alternative NOAEL-based method can be safe while reducing time to the recommended phase 2 dose.

Autor: Jessen BA; Pfizer, Drug Safety Research and Development, San Diego, CA, 92121, USA. bart.jessen@pfizer.com., Cornwell P; Eli Lilly, Nonclinical Safety Assessment, Indianapolis, IN, USA., Redmond S; Clinical Pharmacology & Safety Sciences, AstraZeneca Pharmaceuticals, Waltham, MA, 02451, USA., Visalli T; Eisai Inc., Global Nonclinical Regulatory, Nutley, NJ, 07110, USA., Lemper M; Development Science, UCB, Inc., Cambridge, MA, 02140, USA., Bunch T; Nonclinical Safety Evaluation, Bristol Myers Squibb, Princeton, NJ, 08540, USA., Hart T; GlaxoSmithKline, IVIVT, Collegeville, PA, 19426, USA.

Publikováno v: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2023 Dec; Vol. 92 (6), pp. 455-464. Date of Electronic Publication: 2023 Jul 28.

Extracellular vesicle encapsulated nicotinamide delivered via a trans-scleral route provides retinal ganglion cell neuroprotection.

Autor: Kim, Myungjin¹ (AUTHOR), Kim, Jun Yong^2,3 (AUTHOR), Rhim, Won-Kyu² (AUTHOR), Cimaglia, Gloria⁴ (AUTHOR), Want, Andrew⁴ (AUTHOR), Morgan, James E.^4,5 (AUTHOR), Williams, Pete A.⁶ (AUTHOR), Park, Chun Gwon³ (AUTHOR), Han, Dong Keun² (AUTHOR), Rho, Seungsoo¹ (AUTHOR) harryrho@gmail.com

Publikováno v: Acta Neuropathologica Communications. 4/22/2024, Vol. 12 Issue 1, p1-16. 16p.

Weak base drug-induced endolysosome iron dyshomeostasis controls the generation of reactive oxygen species, mitochondrial depolarization, and cytotoxicity.

Autor: Halcrow, Peter W.¹, Quansah, Darius N. K.¹, Kumar, Nirmal¹, Solloway, Rebecca L.¹, Teigen, Kayla M.¹, Lee, Kasumi A.¹, Liang, Braelyn¹, Geiger, Jonathan D.¹ jonathan.geiger@und.edu

Publikováno v: NeuroImmune Pharmacology & Therapeutics. Mar2024, Vol. 3 Issue 1, p33-46. 14p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies.

Autor: Hu W; Drug Safety Research and Development, Pfizer Inc. San Diego, California. wenyue.hu@pfizer.com., Sung T; Drug Safety Research and Development, Pfizer Inc. San Diego, California., Jessen BA; Drug Safety Research and Development, Pfizer Inc. San Diego, California., Thibault S; Drug Safety Research and Development, Pfizer Inc. San Diego, California., Finkelstein MB; Drug Safety Research and Development, Pfizer Inc. Pearl River, New York., Khan NK; Drug Safety Research and Development, Pfizer Inc. Groton, Connecticut., Sacaan AI; Drug Safety Research and Development, Pfizer Inc. San Diego, California.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 Apr 15; Vol. 22 (8), pp. 2000-8. Date of Electronic Publication: 2015 Dec 02.